Table S2. Cytotoxicity of different PTX formulations in HER2-overexpressing cancer cells (HT-29 and SK-BR-3) and HER2 low-expressing cancer cells (MDA-MB-231).

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | HT-29 | | | SK-BR-3 | | | MDA-MB-231 | | |
| IC50  (nM) | IC100 (nM) | IT50  (h) | IC50  (nM) | IC100  (nM) | IT50  (h) | IC50  (nM) | IC100 (nM) | IT50  (h) |
| PTX | 1.3 ± 0.5 | 10 | 7.6 ± 0.8 | 5.5 ± 1.3 | 30 | 9.1 ± 0.6 | 3.1 ± 0.5 | 30 | 3.3 ± 0.5 |
| gPTX | 11.0 ± 0.8 | 50 | 9.4 ± 1.6 | 18.9 ± 1.1 | 100 | 10.5 ± 2.1 | 7.7 ± 1.3 | 50 | 6.2 ± 2.8 |
| gPTX-L | 7.6 ± 1.3 | 30 | 7.1 ± 0.4 | 6.6 ± 0.9 | 30 | 8.9 ± 1.2 | 4.6 ± 0.6 | 30 | 3.2 ± 0.8 |
| gPTX-IL | 6.7 ± 0.6 | 30 | 4.7 ± 0.7 | 5.3 ± 0.7 | 30 | 6.4 ± 0.8 | 4.9 ± 0.6 | 30 | 3.5 ± 0.7 |

*IC50 and IT50 are presented as the mean ± S.D. (n = 3).*

*IC100 was estimated from the evaluation of cytotoxicity.*